Renin Inhibitors Patents (Class 530/860)
  • Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
    Patent number: 8883145
    Abstract: Methods for treating cancer comprising administering a DLL4 antagonist and one or more anti-hypertensive agents are described. Also described are pharmaceutical compositions comprising a DLL4 antagonist and one or more anti-hypertensive agents, and kits comprising the same.
    Type: Grant
    Filed: October 18, 2010
    Date of Patent: November 11, 2014
    Assignee: Oncomed Pharmaceuticals, Inc.
    Inventors: Robert Joseph Stagg, Steven Eugene Benner
  • Drug screening and diagnosis based on paracrine tubular renin-angiotensin system
    Patent number: 7749725
    Abstract: The present invention relates to a method for screening drugs for use in treating hypertension using the tubular renin-angiotensinogen system identified by the present invention. The invention further relates to a method to diagnose sodium status and sensitivity in an individual by measuring urinary angiotensinogen or angiotensin-I.
    Type: Grant
    Filed: October 16, 2002
    Date of Patent: July 6, 2010
    Assignee: University of Utah Research Foundation
    Inventors: Andreas Rohrwasser, Terry Morgan, Jean-Marc Lalouel
  • Sequences of hepatitis C virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
    Patent number: 7129337
    Abstract: The present invention relates to new genomic nucleotide sequences and amino acid sequences corresponding to the coding region of these genomes. The invention relates to new HCV types and subtypes sequences which are different from the known HCV types and subtypes sequences. More particularly, the present invention relates to new HCV type 7 sequences, new HCV type 9 sequences, new HCV type 10 and new HCV type 11 sequences. Also, the present invention relates to new HCV type 1 sequences of subtypes 1d, 1e, 1f and 1g; new HCV type 2 sequences of subtypes 2e, 2f, 2g, 2h, 2i, 2k and 2l; new HCV type 3 sequences of subtype 3g, new HCV type 4 sequences of subtypes 4k, 4l and 4m; a process for preparing them, and their use for diagnosis, prophylaxis and therapy. More particularly, the present invention provides new type-specific sequences of the Core, the E1 and the NS5 regions of new HCV types 7, 9, 10 and 11, as well as of new variants (subtypes) of HCV types 1, 2, 3 and 4.
    Type: Grant
    Filed: October 23, 1995
    Date of Patent: October 31, 2006
    Assignee: Innogenetics N.V.
    Inventors: Geert Maertens, Lieven Stuyver
  • Diol-containing renin inhibitors
    Patent number: 5260278
    Abstract: The invention concerns novel renin-inhibitory peptides which are useful for treating renin-associated hypertension, congestive heart failure, hyperaldosteronism, and diseases caused by retroviruses including HTLV-I and -III. Processes for preparing the peptides, compositions containing them, and methods of using them are included. Also included is a diagnostic method which uses the compounds to determine the presence of renin-associated hypertension, or hyperaldosteronism.
    Type: Grant
    Filed: April 1, 1991
    Date of Patent: November 9, 1993
    Assignee: Warner-Lambert Company
    Inventors: Richard Himmelsbach, John C. Hodges, James S. Kaltenbronn, William C. Patt, Joseph T. Repine, Ila Sircar